These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31932992)

  • 21. Case report: multiple myeloma presenting as a diastolic heart failure with no evidence of amyloidosis.
    Schattner A; Epstein M; Berrebi A; Caspi A
    Am J Med Sci; 1995 Dec; 310(6):256-7. PubMed ID: 7503107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition of congestive heart failure due to senile cardiac amyloidosis.
    Gertz MA; Kyle RA; Edwards WD
    Biomed Pharmacother; 1989; 43(2):101-6. PubMed ID: 2736272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac Light Chain Deposition Disease Mimicking Immunoglobulin Light Chain Amyloidosis: Two Branches of the Same Tree.
    Osanami A; Yano T; Takemura G; Ikeda H; Inyaku M; Toda Y; Kamiyama N; Sugawara H; Gocho Y; Fujito T; Nagano N; Takahashi S; Muranaka A; Tanaka M; Moniwa N; Murase K; Takada K; Kuroda H; Ogawa Y; Miura T
    Circ Cardiovasc Imaging; 2020 Sep; 13(9):e010478. PubMed ID: 32873072
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiac amyloidosis: a practical approach to diagnosis and management.
    Kapoor P; Thenappan T; Singh E; Kumar S; Greipp PR
    Am J Med; 2011 Nov; 124(11):1006-15. PubMed ID: 22017778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cardiac primitive amyloidosis].
    Scripcaru G; Dobrescu G; Costăchescu G; Ionescu S
    Rev Med Chir Soc Med Nat Iasi; 1982; 86(1):155-7. PubMed ID: 25591271
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
    Badar T; Cornelison AM; Shah ND; Bashir Q; Parmar S; Patel K; Hosing C; Popat U; Weber DM; Thomas SK; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Eur J Haematol; 2016 Oct; 97(4):342-7. PubMed ID: 26773409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal stress echocardiography findings in cardiac amyloidosis.
    Ong KC; Askew JW; Dispenzieri A; Maleszewski JJ; Klarich KW; Anavekar NS; Mulvagh SL; Grogan M
    Amyloid; 2016 Jun; 23(2):124-31. PubMed ID: 27132767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease.
    Finsterer J; Höftberger R; Stöllberger C; Wöhrer A; Regele H
    J Oncol Pharm Pract; 2013 Jun; 19(2):170-4. PubMed ID: 22504167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future directions in the clinical management of amyloid light-chain amyloidosis.
    Haider S; Ahmad N; Anaissie E; Driscoll JJ
    Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac amyloidosis.
    Kingman A; Pereira NL
    J S C Med Assoc; 2001 May; 97(5):201-6. PubMed ID: 11381776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intramural coronary light-chain amyloidosis and left ventricular assist device implantation.
    Kamdar F; Tan CD; Rodriguez ER; Moazami N; Hanna M
    J Heart Lung Transplant; 2020 Oct; 39(10):1163-1164. PubMed ID: 32736937
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent advances in the diagnosis and management of cardiac amyloidosis.
    Sher T; Gertz MA
    Future Cardiol; 2014 Jan; 10(1):131-46. PubMed ID: 24344669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.
    Patel KS; Hawkins PN; Whelan CJ; Gillmore JD
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25535224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options.
    Alkhawam H; Patel D; Nguyen J; Easaw SM; Al-Sadawi M; Syed U; Zaiem F; Homsi M; Vittorio TJ
    Acta Cardiol; 2017 Aug; 72(4):380-389. PubMed ID: 28705053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis.
    Decker I; Goodman SA; Phillips SE; Lenihan DJ; Cornell RF
    Br J Haematol; 2017 May; 177(3):481-483. PubMed ID: 28295184
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiac amyloidosis: approaches to diagnosis and management.
    Desai HV; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2010; 18(1):1-11. PubMed ID: 20010333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.
    Brenner DA; Jain M; Pimentel DR; Wang B; Connors LH; Skinner M; Apstein CS; Liao R
    Circ Res; 2004 Apr; 94(8):1008-10. PubMed ID: 15044325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Contribution of myocardial biopsy and immunohistochemistry to the prognostic evaluation of cardiac amyloidosis].
    Van de Walle JP; Fourcade L; Panagides D; Harle JR; Pellissier JF; Touze JE; Bory M
    Arch Mal Coeur Vaiss; 1994 Feb; 87(2):235-9. PubMed ID: 7802531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid heart disease.
    Falk RH; Dubrey SW
    Prog Cardiovasc Dis; 2010; 52(4):347-61. PubMed ID: 20109604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.